



PATENT

#12

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF MAILING

I hereby certify that this **INFORMATION DISCLOSURE STATEMENT** and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Ariel Fletcher

Date

6/9/2003

RECEIVED

JUN 16 2003

TECH CENTER 1600/2900

Applicant: Burton, et al.	)	
	)	Group: 1648
Serial No.: 10/016,986	)	
	)	
Filed: December 12, 2001	)	Examiner: Unassigned
	)	
For: HUMAN NEUTRALIZING	)	
MONOCLONAL ANTIBODIES TO	)	Our Ref.: TSRI 313.2 Con. 1
HUMAN IMMUNODEFICIENCY VIRUS	)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the application 08/276,852 which refers to and also includes Information Disclosure Statements filed in other related applications. Application 08/276,852 was filed on July 18, 1994, and has issued as U.S. Patent No. 5,652,138, to which the present application is related by continuation. Also,

pursuant to 37 CFR \$1.98(d), copies of the above references are not submitted herewith, as they are available in the related patent application 08/276,852 and other related applications.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR \$1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR \$1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.

Also, in accordance with 37 CFR \$1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR \$1.56 exists.

Respectfully submitted,

June 09, 2003  
Date

Michael J. McCarthy  
Michael J. McCarthy, Reg. No. 46,910

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(858) 784-2937

P:\NancyB\WP\2003\IDS\TSR0504P.wpd



RECEIVED  
JUN 16 2003  
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Thomas Fitting  
Thomas Fitting, Reg. No. 34,163

JUN 10, 1995  
Date

Applicant	:	Burton, et al.	)
			) Group Art Unit: Unknown
Serial No.	:	08/276,852	)
			)
Filed	:	July 18, 1994	) Examiner: Unknown
			)
For	:	HUMAN NEUTRALIZING	)
		MONOCLONAL ANTIBODIES TO	)
		HUMAN IMMUNODEFICIENCY	)
		VIRUS	) Our Ref. TSRI 313.2
			)
			)
			)

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith. Copies of the references cited therein are also enclosed.

The following references were cited in the application and are believed relevant for the reasons set forth in the specification:

1. Kang, et al., Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991)
2. Kang, et al., Proc. Natl. Acad. Sci. USA, 88:11120-11123-4366 (1991)

Kang, et al., Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991) describes the use of the filamentous phage coat protein membrane anchor domain cpVIII as a means for linking gene-product and gene during the assembly stage of filamentous phage replication and the use of this technology for the cloning and expression of antibodies. Kang, et al., Proc. Natl. Acad. Sci. USA, 88:11120-11123-4366 (1991) describes a method to increase the diversity of a filamentous phage-based combinatorial antibody library by shuffling of the heavy and light chain genes.

The following references were cited during the prosecution of related U.S. patent Application Serial No. 07/954,148, now abandoned, and are believed relevant for that reason:

1. Berkower, et al., J. Virol., 65: 5983-5990 (1991)
2. Broliden, et al., Immunology, 73: 371-376 (1991)
3. Burton, et al., PNAS, USA, 88: 10134-10137 (1991)
4. D'Souza, et al., AIDS, 1061-1070 (1991)
5. Gorny, et al., PNAS, USA, 88: 3238-3242 (1991)
6. Ho, et al., J. Virol., 65: 489-493 (1991)
7. Ho, et al., PNAS, USA, 88: 8949-8952 (1991)
8. Jackson, et al., Lancet, September 17, 1988, pp. 647-651
9. Kang, et al., PNAS, USA, 88: 6171-6175 (1991)
10. Karpas, et al., PNAS, USA, 87: 7613-7617 (1990)
11. Karwowska, et al., AIDS Res. and Hum. Retroviruses, 8: 1099-1106 (1992)
12. Laman, et al., J. Virol., 66: 1823-1831 (1992)
13. Linsley, et al., J. Virol., 62: 3695-3702 (1988)
14. McKeating, et al., AIDS, 3: 777-784 (1989)
15. Nara, et al., AIDS Res. and Hum. Retroviruses, 3: 283-302 (1987)
16. Nara, et al., FASEB J., 5: 2437-2455 (1991)
17. Posner, et al., J. Immunol., 146: 4325-4332 (1991)
18. Skinner, et al., J. Virol., 62: 4195-4200 (1988)
19. Steimer, et al., Science, 254: 105-108 (1991)

20. Takeda, et al., J. Clin Invest., 89: 1952-1957 (1992)
21. Thali, et al., J. Virol., 65: 6188-6193 (1991)
22. Tilley, et al., AIDS Res. and Hum. Retroviruses, 8: 461-467 (1992)
23. Tilley, et al., Res. Virol., 142: 247-259 (1991)
24. Wahlberg, et al., AIDS Res. and Hum. Retroviruses, 7: 983-990 (1991)

Pursuant to 37 CFR §1.98(d), copies of the references listed above are not submitted herewith, as they are available in the related U.S. patent Application Serial No. 07/954,148, relied upon for an earlier filing date. However, for the convenience of the Examiner, the references are listed above, and a copy of Information Disclosure Statement and PTO Form 1449 is enclosed.

The following references were cited in the Search Report of the PCT patent Application No. PCT/US 93/09328 corresponding to the above-referenced U.S. application and are believed relevant for that reason:

1. Burton, et al., Proc. Natl. Acad. Sci., USA, 88: 10134-10137 (1991)
2. Ho, et al., J. Virol., 65: 489-493 (1991)
3. Gorny, et al., Proc. Natl. Acad. Sci., USA, 88: 3238-3242 (1991)
4. Posner, et al., J. Immunol., 146: 4325-4332 (1991)
5. Tilley, et al., Res. Virol., 142: 247-259 (1991)
6. Karwowska, et al., Aids Res. and Hum. Retroviruses, 8: 1099-1106 (1992)

Pursuant to 37 CFR §1.98(d), copies of the following references are not submitted herewith, as they are available in the

PCT patent Application PCT/US 93/09328, relied upon for an earlier filing date. However, for the convenience of the Examiner, a copy of the Search Report is enclosed.

Additional relevant references have not been cited during the prosecution of copending, related US patent Application Serial No. 08/178,302.


Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (b) insofar as this statement is being filed before the mailing date of a first Office Action.

Also in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 1/10/95

By:   
Thomas Fitting  
Registration No. 34,163  
THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10666 N. Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(619) 554-2937

rlm\C:\WP\IDS\SCR1452P\SCR1452P.RES

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE



ATTY DOCKET NO.  
TSRI 313.2

SERIAL NO.  
08/276,852

APPLICANT  
Burton, et al.

FILING DATE  
July 18, 1994

GROUP  
Unknown

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1	Kang, et al., <u>Proc. Natl. Acad. Sci. USA</u> , 88:4363-4366 (1991)
2	Kang, et al., <u>Proc. Natl. Acad. Sci. USA</u> , 88:11120-11123 (1991)
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED  
JUN 16 2003  
TECH CENTER 1800/2900



RECEIVED  
JUN 16 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on the date written below.

Thomas Fitting  
Thomas Fitting, Reg. No. 34,163

October 29, 1992  
Date of Deposit

Applicant: Burton, et al.	)	
Serial No: 07/954,148	)	
Filed: September 30, 1992	)	Group Art
	)	Unit: Unassigned
For: HUMAN NEUTRALIZING MONOCLONAL	)	
ANTIBODIES TO HUMAN	)	
IMMUNODEFICIENCY VIRUS	)	
Examiner: Unassigned	)	Our Ref. No. SCR 1134P
	)	October 29, 1992

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith. Copies of the references cited therein are also enclosed.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.



Applicants are filing the present statement pursuant to 37 CFR 1.97 (b) insofar as this statement is being filed before the mailing date of a first Office Action.

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 10/27/92

By Thomas Fitting

Thomas Fitting  
THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10666 N. Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(619) 554-2937

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT



ATTY DOCKET NO.  
TSRI 313.2 Con 1

SERIAL NO.  
10/016,988

APPLICANT  
Burton, Barbas, Lerner

FILING DATE  
12/12/2001

GROUP

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	1	5,652,138	07/29/97	Burton, et al.	435	252.33	
	2	5,804,440	09/08/98	Burton, et al.	435	339.1	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Barbas, et al. <i>J. Mol. Bio.</i> , 230: 812-823 (1993)
	2	Barbas, et al. <i>PNAS USA</i> , 89(19): 9339-9343 (1992)
	3	Barbas, et al. <i>PNAS USA</i> , 91: 3809-3813 (1994)
	4	Bender, et al. <i>Human Antibodies and Hybridomas</i> , 4: 74-79 (1993)
	5	Buchacher, et al. <i>Vaccines</i> 92: 191-195 (1992)
	6	Burton, et al. <i>Science</i> , 266: 1024-1027 (1994)
	7	Fahey, et al. <i>Clin. Exp. Immunol.</i> , 88: 1-5 (1992)
	8	Fox, JL. <i>Bio/Technology</i> , 12: 128 (1994)
	9	Krust, et al. <i>AIDS</i> , 2(1): 17-24 (1988)
	10	Moore, et al. <i>J. Virology</i> , 69(1): 101-109 (1995)
	11	Roben, et al. <i>J. Virology</i> , 68(8): 4821-4828 (1994)
	12	Zebedee, et al. <i>PNAS USA</i> , 89(8): 3175-3179 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE



ATTY DOCKET NO.  
SCR 1134P

SERIAL NO.  
07/954,148

APPLICANT  
Burton, et al.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

FILING DATE  
September 30, 1992

GROUP  
Unassigned

## U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

RECEIVED

JUN 16 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1	Berkower, et al., <u>J. Virology</u> , 65: 5983-5990 (1991)
2	Broliden, et al., <u>Immunology</u> , 73: 371-376 (1991)
3	Burton, et al., <u>PNAS, USA</u> , 88: 10134-10137 (1991)
4	D'Souza, et al., <u>AIDS</u> , 1061-1070 (1991)
5	Gorny, et al., <u>PNAS, USA</u> , 88: 3238-3242 (1991)
6	Ho, et al., <u>J. Virology</u> , 65: 489-493 (1991)
7	Ho, et al., <u>PNAS, USA</u> , 88: 8949-8952 (1991)
8	Jackson, et al., <u>Lancet</u> , September 17, 1988, pp. 647-651
9	Kang, et al., <u>PNAS, USA</u> , 88: 6171-6175 (1991)
10	Karpas, et al., <u>PNAS, USA</u> , 87: 7613-7617 (1990)
11	Karwowska, et al., <u>AIDS Res. and Human Retroviruses</u> , 8: 1099-1106 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

LB\C:\FORMS\SCR11341.449



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.  
SCR 1134P

SERIAL NO.  
07/954,148

APPLICANT  
Burton, et al.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

FILING DATE  
September 30, 1991

GROUP  
Unassigned

### U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

RECEIVED

JUN 16 2003

TECH CENTER 1600/2900

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

12	Laman, et al., <u>J. Virol.</u> , 66: 1823-1831 (1992)
13	Linsley, et al., <u>J. Virol.</u> , 62: 3695-3702 (1988)
14	McKeating, et al., <u>AIDS</u> , 3: 777-784 (1989)
15	Nara, et al., <u>AIDS Res. and Human Retroviruses</u> , 3: 283-302 (1987)
16	Nara, et al., <u>FASEB J.</u> , 5: 2437-2455 (1991)
17	Posner, et al., <u>J. Immunol.</u> , 146: 4325-4332 (1991)
18	Skinner, et al., <u>J. Virol.</u> , 62: 4195-4200 (1988)
19	Steimer, et al., <u>Science</u> , 254: 105-108 (1991)
20	Takeda, et al., <u>J. Clin. Invest.</u> , 89: 1952-1957 (1992)
21	Thali, et al., <u>J. Virol.</u> , 65: 6188-6193 (1991)
22	Tilley, et al., <u>AIDS Res. and Human Retroviruses</u> , 8: 461-467 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\\C:\FORMS\SCR11342.449

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

SERIAL NO.  
07/954,148

APPLICANT  
Burton, et al.

FILING DATE  
September 30, 1991

GROUP  
Unassigned

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

[illegible]

EXAMINER

DATE CONSIDERED

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.